JT

Julien Torgue

Chief Scientific Officer at Orano Med

Julien Torgue has extensive work experience in the scientific and research field. From 2018 to the present, they have served as the Chief Scientific Officer at Orano Med, formerly known as AREVA Med. Prior to this role, they held the position of Scientific Director at Orano Med from 2010 to 2018. In addition, Julien has been a Board Member at Orano Med since 2017.

Julien Torgue's other work experiences include a role as a Board Member at Macrocyclics since 2015, a Senior Scientist & Project Manager at Paragon Bioservices, Inc. in 2010, and a Project Manager at Goodwin Biotechnology, Inc. from 2007 to 2010.

Julien's research experience includes a Research Assistant role at the Florida Institute of Technology from 2003 to 2007, where they conducted experiments on DNA replication initiation and developed methods to study DNA-protein interactions. Julien also collaborated with Dr. Shoahua Xu at NASA from 2005 to 2007 to measure DNA-protein complex assemblies using atomic force microscopy. Additionally, Julien completed a Research Internship in the hepacivirus unit at Institut Pasteur in 2003.

Julien Torgue has a strong education history that spans multiple fields. Julien began their education at the Ecole Active Bilingue de Paris, where they earned a Bac S degree with a focus on OIB from 1985 to 2000. Following this, they attended the Florida Institute of Technology from 2000 to 2003 and obtained a Bachelor of Science degree in Biochemistry. Julien continued their education at the same institution and earned a Ph.D. in Molecular Biology from 2003 to 2007.

In addition to their impressive academic achievements, Julien Torgue has also obtained certifications in various areas. In 2009, they became a Quality Improvement Associate with a CQIA certification from ASQ. Furthermore, in 2012, they obtained a Regulatory Affairs Certificate in Pharmaceuticals from the Regulatory Affairs Professionals Society (RAPS).

Julien Torgue's diverse educational background, coupled with their certifications, demonstrates their dedication and expertise in both scientific and regulatory fields.

Location

Gaithersburg, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Orano Med

1 followers

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.


Employees

51-200

Links